Ferroptosis is fundamentally a lipid chemistry problem. Unlike apoptosis, which proceeds through genetically scripted signaling cascades, ferroptosis occurs when iron-catalyzed chemical reactions, akin to Fenton chemistry, attack the polyunsaturated fatty acids within membrane phospholipids and convert them into destructive lipid hydroperoxides. Phosphatidylethanolamines carrying two polyunsaturated fatty acyl tails are particularly dangerous substrates, because their bis-allylic hydrogen atoms are easily abstracted by free radicals, initiating peroxidation chain reactions that rupture the membrane and kill the cell. The cell’s principal defense is the enzyme glutathione peroxidase 4, or GPX4, which reduces these phospholipid hydroperoxides back to harmless lipid alcohols, while a parallel suppressor, ferroptosis suppressor protein 1, or FSP1, quenches lipid radicals independently of glutathione. The balance between the production of oxidizable polyunsaturated phospholipids and their repair defines a cell’s ferroptotic sensitivity.

The central proposal of the new review is that in cholangiocarcinoma this balance may be governed by a specific molecular ratio: the abundance of membrane phosphatidylethanolamines containing monounsaturated fatty acids relative to those containing polyunsaturated fatty acids. The authors term this proposed dynamic equilibrium the ferroptotic rheostat. Monounsaturated fatty acids lack the vulnerable bis-allylic positions that make their polyunsaturated cousins susceptible to peroxidation, so when they are incorporated into membrane phospholipids they dilute the pool of oxidizable substrates and render the membrane chemically resistant to ferroptotic execution. The review argues, as an explicit working hypothesis rather than an established mechanism, that the position of this MUFA-PE to PUFA-PE ratio may be a principal determinant of ferroptotic fate in bile duct cancer cells.

The most direct evidence for this idea in cholangiocarcinoma comes from a single untargeted lipidomic study of four cholangiocarcinoma cell lines, published by Sae-Fung and colleagues in npj Precision Oncology in 2024. That work identified acyl-CoA synthetase long-chain family member 4, ACSL4, as the enzyme that channels polyunsaturated fatty acids into membrane phospholipids and thereby promotes ferroptosis sensitivity, while its isoform ACSL3 preferentially activates monounsaturated fatty acids such as oleate for incorporation into membranes. In the cholangiocarcinoma cell lines examined, ACSL3-driven enrichment of monounsaturated phosphatidylethanolamines conferred resistance to ferroptosis, and ACSL3 expression emerged as an unfavorable prognostic marker in patient cohorts. The review is careful to flag that this remains the only CCA-specific, functionally integrated evidence for a membrane-lipid-based resistance mechanism, and that the critical ratio has never been measured directly in human cholangiocarcinoma tumor tissue.

Upstream of ACSL3, the review situates the rheostat within the broader machinery of de novo lipogenesis. The fatty acid synthase FASN manufactures the saturated fatty acid palmitate, which the enzyme stearoyl-CoA desaturase 1, SCD1, then desaturates into monounsaturated species that can be deployed into membranes as ferroptosis-proofing material. ATP-citrate lyase, ACLY, supplies the acetyl-CoA substrate that feeds this entire lipogenic pipeline by cleaving citrate exported from the mitochondrion. Each of these enzymes has been implicated in cholangiocarcinoma progression through transcriptomic and functional studies: FASN-mediated fatty acid biosynthesis remodels the immune environment of parasite-associated intrahepatic cholangiocarcinoma, a circular RNA called MBOAT2 promotes tumor progression by stabilizing the messenger RNA of FASN, ACLY shows pathological significance and prognostic value in patient samples, and pharmacological degradation of acetyl-CoA carboxylase 1 attenuates lipid accumulation and tumor growth. The review stresses, however, that apart from the ACSL3-MUFA axis, the individual links connecting these lipogenic enzymes to ferroptosis resistance in cholangiocarcinoma rest largely on bioinformatic inference or evidence imported from other tumor types rather than on direct redox lipidomic measurement in human bile duct cancer tissue.

What distinguishes cholangiocarcinoma from most other cancers is its intimate exposure to bile, and the review devotes particular attention to a crosstalk axis that is essentially unique to this tumor’s microenvironment. Bile acids, the detergent-like molecules that cholangiocytes bathe in daily, activate the farnesoid X receptor, FXR, a nuclear receptor that regulates lipid homeostasis. Work in hepatocyte models has shown that FXR activation by bile acids suppresses lipid peroxidation and protects cells from ferroptosis, raising the tantalizing possibility that the bile acid-rich environment of the biliary tree continuously pushes the ferroptotic rheostat toward resistance in cholangiocarcinoma cells. The authors are explicit that this prediction, derived from hepatocyte studies, has not yet been tested in cholangiocarcinoma itself, and they flag it as a hypothesis in need of direct experimental validation. Given that cholestasis and altered bile acid composition are hallmark features of the biliary diseases that predispose patients to cholangiocarcinoma, this axis represents one of the most distinctive and clinically relevant frontiers of the proposed model.

The review also identifies a genetically defined entry point for ferroptosis sensitization in a subset of patients. Roughly fifteen to twenty percent of intrahepatic cholangiocarcinomas carry mutations in the metabolic enzymes isocitrate dehydrogenase 1 or 2, IDH1 and IDH2. These mutations cause the enzymes to produce the oncometabolite 2-hydroxyglutarate, which competitively inhibits alpha-ketoglutarate-dependent dioxygenases and drives epigenetic dysregulation. Crucially for ferroptosis biology, the mutant enzymes also consume NADPH, the reducing equivalent that cells need to regenerate their antioxidant defenses, including the CoQ10 pool maintained by FSP1. Studies in cell models have shown that 2-hydroxyglutarate production by mutant IDH1 sensitizes cells to ferroptosis through this NADPH depletion, and circulating 2-hydroxyglutarate is already being explored as a biomarker in IDH-mutant cholangiocarcinoma patients. This suggests that a molecularly defined subgroup of bile duct cancers may be intrinsically more vulnerable to ferroptosis-inducing therapies, an idea that could be exploited with existing IDH inhibitors or ferroptosis-inducing compounds.

Beyond the lipogenic and bile acid axes, the review surveys a crowded landscape of ferroptosis regulators implicated in cholangiocarcinoma by recent functional studies. The cystine transporter SLC7A11, which imports the amino acid needed for glutathione synthesis, is upregulated by the Golgi phosphoprotein GOLPH3 and by the m6A methyltransferase METTL16, both of which suppress ferroptosis and promote malignancy. The tumor suppressor p53 and its metabolic effector TP53-induced glycolysis and apoptosis regulator influence ferroptotic resistance in intrahepatic tumors, while large-scale functional genomic screens have revealed differential dependence on GPX4 between intrahepatic and extrahepatic cholangiocarcinoma. Iron metabolism itself is dysregulated in cholangiocarcinoma stem-like cells, and the ferritinophagy receptor NCOA4, which liberates iron from ferritin stores, has emerged as a potential therapeutic target. Each of these findings adds a layer to the regulatory network that ultimately converges on the same endpoint: the oxidation state of the membrane phospholipid pool.

Perhaps the most valuable contribution of the review is its unflinching honesty about the state of the evidence. The authors state at the outset that the ferroptotic rheostat is a proposed model, not an established mechanism, and they systematically flag which links in the framework are supported by direct measurement and which rest on transcriptomic correlation or cross-tumor extrapolation. They conclude by outlining the priority research gaps that must be closed before any lipid-centric intervention strategy could be considered in patients. Foremost among these is the systematic application of redox phospholipidomics, using liquid chromatography coupled to high-resolution mass spectrometry to quantify oxidized phospholipid species directly, and spatial lipidomics, which maps lipid distributions within intact tissue sections, to human cholangiocarcinoma biospecimens. Only such measurements, the authors argue, can test, refute, or refine the model. If validated, the rheostat concept would reframe ferroptosis from a binary switch into a tunable parameter, opening a rational path toward combination therapies that first strip the monounsaturated armor from cancer cell membranes with SCD1 or FASN inhibitors, and then trigger the peroxidative collapse that the sensitized membrane can no longer withstand.

Subject of Research: The role of membrane lipid composition, particularly the MUFA-PE to PUFA-PE ratio, in regulating ferroptosis sensitivity in cholangiocarcinoma

Article Title: Lipidome as a ferroptotic rheostat in cholangiocarcinoma: A proposed model and its current evidence base

Article References: Köse-Demirtaş, B., & Kurtoğlu, D. (2026). Lipidome as a ferroptotic rheostat in cholangiocarcinoma: A proposed model and its current evidence base. Molecular Biology Reports, 53(1), Article 1636. https://doi.org/10.1007/s11033-026-12819-2

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12819-2

Keywords: cholangiocarcinoma, ferroptosis, lipidomics, lipid peroxidation, ACSL3, SCD1, FASN, bile acids, FXR, IDH1/2 mutations, phospholipids, metabolic reprogramming